Faheem, A., Elsayed Nabawy, S., Mobark, A. (2024). Metformin versus Low Dose Aspirin In Prevention of Hypertensive Disorders in Pregnant Obese Women. test, 5(4), 44-56. doi: 10.21608/ejmr.2024.244103.1483
Ashraf Samir Faheem; Safaa Abd Elazeem Elsayed Nabawy; Ali Mobark. "Metformin versus Low Dose Aspirin In Prevention of Hypertensive Disorders in Pregnant Obese Women". test, 5, 4, 2024, 44-56. doi: 10.21608/ejmr.2024.244103.1483
Faheem, A., Elsayed Nabawy, S., Mobark, A. (2024). 'Metformin versus Low Dose Aspirin In Prevention of Hypertensive Disorders in Pregnant Obese Women', test, 5(4), pp. 44-56. doi: 10.21608/ejmr.2024.244103.1483
Faheem, A., Elsayed Nabawy, S., Mobark, A. Metformin versus Low Dose Aspirin In Prevention of Hypertensive Disorders in Pregnant Obese Women. test, 2024; 5(4): 44-56. doi: 10.21608/ejmr.2024.244103.1483

Metformin versus Low Dose Aspirin In Prevention of Hypertensive Disorders in Pregnant Obese Women

Egyptian Journal of Medical Research
Volume 5, Issue 4, October 2024, Pages 44-56    PDF (538.32 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2024.244103.1483
Authors
Ashraf Samir Faheem; Safaa Abd Elazeem Elsayed Nabawy* ; Ali Mobark
Obstetrics and Gynecology Department, Faculty of Medicine, Beni-Suef University
Abstract
Background: Hypertensive disorders in Pregnant obese women are associated with increased risk of maternal mortality and morbidity, metformin and aspirin have been reported to reduce the risk of them. Aim of the Work: to compare the effect of metformin versus low dose aspirin in prevention of hypertensive disorders in pregnant obese patients. Patients and Methods: During this study, 345 patients were assessed for eligibility and 300 patients were included in the study (100 in each group). First group received metformin started from 12 to 13 weeks till delivery at dose 1 g /day. Second group received Low dose aspirin at dose 150 mg daily from 12 to 13 weeks till delivery. Third group was the control group. In this study, we followed up each group at ANC visit and all patients were clinically examined. Results: Maternal weight gain during pregnancy at weeks 30 and 34 statistically was significantly lowest in metformin group (p value=0.016, <0.001) respectively, Hypertensive disorders of pregnancy, gestational hypertension and Preeclampsia were least frequent in metformin group, followed by aspirin group and most frequent in control group, the differences statistically were significant (p value<0.001, 0, 026, 0.019) respectively, marked lower limb edema was least frequent in metformin group and most frequent in control group, regarding preterm delivery was least frequent in metformin group, followed by aspirin group and most frequent in control group. Conclusion: Prophylactic therapy with a daily dose of 1.0 g of metformin in pregnant obese women without diabetes mellitus from 12 to 13 weeks of gestation until delivery was associated with less hypertensive disorders, less maternal gestational weight gain and less neonatal preterm delivery than that observed with aspirin and control groups.
Keywords
Metformin versus low dose aspirin; Hypertensive disorders; Pregnant obese women
References
  1. Cushen, S. C., & Goulopoulou, S. (2017). New models of pregnancy-associated hypertension. American journal of hypertension, 30(11), 1053-1062.
  2. Sisti, G., & Colombi, I. (2019). New blood pressure cut off for preeclampsia definition: 130/80 mmHg. European Journal of Obstetrics and Gynecology and Reproductive Biology, 240, 322-324.
  3. Gaillard, R., Steegers, E. A., Hofman, A., & Jaddoe, V. W. (2011). Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Journal of hypertension, 29(5), 937-944.
  4. Cadavid, A. P. (2017). Aspirin: the mechanism of action revisited in the context of pregnancy complications. Frontiers in immunology, 8, 261-269.
  5. Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019). Pre-eclampsia: pathophysiology and clinical implications. BMJ, 366, l2381
  6. Syngelaki, A., Nicolaides, K. H., Balani, , Hyer, S., Akolekar, R., Kotecha, R., & Shehata, H. (2016). Metformin versus placebo in obese pregnant women without diabetes mellitus. New England Journal of Medicine, 374(5), 434-443.
  7. Poniedziałek-Czajkowska, , Mierzyński, R., Dłuski, D., & Leszczyńska-Gorzelak, B. (2021). Prevention of Hypertensive Disorders of Pregnancy—Is There a Place for Metformin?. Journal of Clinical Medicine, 10(13), 2805.
  8. Nascimento, I. B. D., Sales, W. B., Dienstmann, G., Souza, M. L. R. , Fleig, R., & Silva, J. C. (2020). Metformin for prevention of cesarean delivery and large-for-gestational-age newborns in non-diabetic obese pregnant women: a randomized clinical trial. Archives of endocrinology and metabolism, 64, 290-297.
  9. Lin, L., Huai, J., Li, B., Zhu, Y., Juan, , Zhang, M., & Yang, H. (2022). A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China. American Journal of Obstetrics and Gynecology, 226(2), 251-e1.
  10. Chiswick, C., Reynolds, R. M., Denison, F., Drake, A. J., Forbes, S., Newby, D. E., & Norman, J. E. (2015). Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo- controlled trial. The lancet Diabetes & endocrinology, 3(10), 778-786.
Statistics
Article View: 157
PDF Download: 70